NNOX News & Events

Nano-X Imaging announced that the United States Food and Drug Administration, FDA, has granted 510(k) clearance for TAP2D, a new cloud enabled image enhancement capability for the Nanox.ARC and Nanox.ARC X digital tomosynthesis systems. This clearance marks an important step in Nanox's regulatory strategy to position its tomosynthesis systems as primary diagnostic solutions and advances the Company's commitment to increased access to innovative medical imaging solutions. "The newly cleared enhancement capability provides radiologists with an additional, clear 2D view, generated from the digital tomosynthesis scan. The feature is designed to support evaluation while maintaining a smooth workflow for users. The additional view is automatically delivered within the existing clinical environment without adding complexity for clinicians or operators," the company said.

Nanox Imaging announced a new collaboration with Adriamed d.o.o. Beograd, a Belgrade-based medical device distributor serving healthcare providers across Southeast Europe, and part of the Adriamed Group. Under the terms of the agreement, Adriamed becomes Nanox's exclusive partner for the Nanox.ARC system and related services in the region, overseeing all aspects of marketing, distribution, installation, and support.

Nano-X Imaging announced a distribution collaboration with Althea France SARL, part of the Althea Group, to introduce Nanox's advanced imaging solutions to healthcare providers across France. Under the terms of the engagement, Althea France will lead the market introduction, sales and service of Nanox's medical imaging solution, the Nanox.ARC. Following its CE Mark certification, the Nanox.ARC is cleared for commercialization across the European Union

NANO-X IMAGING announced that its deep-learning medical imaging analytics subsidiary, Nanox.AI secured the recommendation of the National Institute for Health and Care Excellence, the UK's clinical standards and reimbursement body. NICE has included both Nanox AI bone solutions in an Early Value Assessment at National Health Service hospitals in the UK. NICE has included Nanox AI's HealthVCF and HealthOST, along with three other AI solutions, for evaluation in NHS hospitals to provide evidence of how AI can help support the detection of vertebral fragility fractures, while further data on their benefits is gathered and assessed. HealthOST is the evolution of HealthVCF, which was evaluated in the AI-enabled Detection of OsteoPorosis study.